Therapeutic agent for covid-19
US-2024325386-A1 · Oct 3, 2024 · US
US10519117B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10519117-B2 |
| Application number | US-201916293100-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 5, 2019 |
| Priority date | Jun 9, 2015 |
| Publication date | Dec 31, 2019 |
| Grant date | Dec 31, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The purpose of the present invention is to provide a method for producing 6-bromo-3-hydroxy-2-pyrazinecarboxamide in which the content ratio of impurities is reduced. This production method includes a step of obtaining 6-bromo-3-hydroxy-2-pyrazinecarboxamide crystal having diffraction angles expressed in degrees 2θ of 5.5, 20.1, 23.7, 26.7, 27.5, and 28.1° and/or diffraction angles expressed in degrees 2θ of 7.1, 21.4, 25.2, 25.7, 27.1, and 28.8° in powder X-ray diffraction.
Opening claim text (preview).
The invention claimed is: 1. A type-A crystal of 6-bromo-3-hydroxy-2-pyrazinecarboxamide having powder X-ray diffraction angles (2θ) of 5.5°, 20.1°, 23.7°, 26.7°, 27.5° and 28.1°. 2. A method for producing a type-A crystal of 6-bromo-3-hydroxy-2-pyrazinecarboxamide, wherein the method comprises: (1) adding anhydrous 3-hydroxy-2-pyrazinecarboxamide having powder X-ray diffraction angles (2θ) of 11.9°, 13.2°, 23.9°, and 26.7° to N,N-dimethylformamide to form a suspension; (2) reacting the suspension formed in the adding above with bromine to produce a mixture; and (3) obtaining a type-A crystal of 6-bromo-3-hydroxy-2-pyrazinecarboxamide having powder X-ray diffraction angles (2θ) of 5.5°, 20.1°, 23.7°, 26.7°, 27.5° and 28.1°. 3. The method of claim 2 , wherein the adding is performed in the presence of pyridine. 4. The method of claim 2 , wherein the method further comprises adding toluene to the mixture. 5. The method of claim 4 , wherein the toluene is added at a temperature in the range of 70° C. to 75° C. 6. The method of claim 5 , wherein the method further comprises adding water to the mixture. 7. The method of claim 6 , wherein the water is added at a temperature in the range of 38° C. to 45° C. 8. The method of claim 7 , wherein the mixture is cooled to 10° C. 9. The method of claim 8 , wherein the type-A crystal of 6-bromo-3-hydroxy-2-pyrazinecarboxamide is obtained by filtration. 10. A method for producing a type-A crystal of 6-bromo-3-hydroxy-2-pyrazinecarboxamide, wherein the method comprises: (1) adding a type-B crystal of 6-bromo-3-hydroxy-2-pyrazinecarboxamide having powder X-ray diffraction angles (2θ) of 7.1°, 21.4°, 25.2°, 25.7°, 27.1° and 28.8° to N,N-dimethylformamide in the presence of activated carbon to form a suspension; (2) filtering the suspension formed in the adding above; (3) washing the filter cake obtained in the filtering above with N,N-dimethylformamide; (4) adding water to the combined filtrates formed in the filtering and the washing above to form a mixture; and (5) obtaining a type-A crystal of 6-bromo-3-hydroxy-2-pyrazinecarboxamide having powder X-ray diffraction angles (2θ) of 5.5°, 20.1°, 23.7°, 26.7°, 27.5° and 28.1°. 11. The method of claim 10 , wherein the adding and the filtering are performed at a temperature of 50° C. 12. The method of claim 10 , wherein the adding of water is performed at a temperature of 50° C. 13. The method of claim 12 , wherein the mixture is cooled to 10° C. 14. The method of claim 13 , wherein the type-A crystal of 6-bromo-3-hydroxy-2-pyrazinecarboxamide is obtained by filtration.
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
Crystalline forms, e.g. polymorphs · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.